Chronic mucocutaneous candidiasis is an immune disorder of T cells marked by long-lasting infections with Candida fungi that stay on the mucous membranes, skin and nails. It can also come with other infections, such as human papilloma virus, and with endocrine dysfunction, vitiligo, malabsorption syndromes and neoplasms. In most patients the cause is abnormal cell-mediated immunity: T lymphocytes fail to produce the cytokines needed for defense against Candida, and mutations that affect the interleukin-17 pathway weaken the immune response. It can be inherited in an autosomal dominant or autosomal recessive way, with nine recognized types, the first of them (CANDF1) mapped to chromosome 2. Recorded signs include thickened skin, skin ulcers, vision problems, hepatitis, seizures and meningitis. Management uses systemic antifungal therapy such as fluconazole, transfer factor and combination therapy, and relapse often follows when treatment stops. Patients with autosomal dominant disease may be at risk of esophageal cancer from nitrosamines produced by chronic Candida infection. This entry records what is documented and is not medical advice.
Facts
Classification
Body SystemLymphatic or Immune System 1 Communicable or Non-communicable Transmission Route Causative Agent
Causative Agent (category) Causative Agent (category) Connections
Treated By
Source Chronic mucocutaneous candidiasis (Wikipedia)
Sources
1. Chronic mucocutaneous candidiasis (Wikipedia)
Lead, nature of the disorder
Chronic mucocutaneous candidiasis is an immune disorder of T cells.
Lead, sites of infection
It is characterized by chronic infections with Candida that are limited to mucosal surfaces, skin, and nails.
Lead, fungal infection
It is characterized by chronic infections with Candida that are limited to mucosal surfaces, skin, and nails.
Cause, inheritance
Chronic mucocutaneous candidiasis can be inherited either autosomal dominant or autosomal recessive.
Cause, genetic types
There are 9 types of this condition with the first CANDF1 being located at 2p22.3-p21 (cytogenetically).
Mechanism, IL-17 pathway
Chronic mucocutaneous candidiasis mutations affect IL-17 by inhibiting its pathway.
Treated By: Antifungal Therapy, Treatment
Systemic anti-fungal therapy (e.g., Fluconazole)
View the Source2. EMBL-EBI Ontology Lookup Service: chronic mucocutaneous candidiasis (Disease Ontology, OLS4)
EMBL-EBI Ontology Lookup ServiceDefinitionQuote, Definition
due to T-cell defects, has-agent Candida species
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.